Development of filtration-based time-resolved fluorescence assay for the high-throughput screening of urotensin II receptor antagonist.
Assay Drug Dev Technol
; 9(5): 514-21, 2011 Oct.
Article
de En
| MEDLINE
| ID: mdl-21561377
The time-resolved fluorescence (TRF) receptor binding assay has many advantages over the traditional radioligand binding assay in terms of sensitivity and reproducibility for the screening of receptor ligands. The TRF-based urotensin receptor (UT) binding assay with an automatic vacuum filtration system was developed and evaluated for the high-throughput screening of UT receptor antagonists. For this assay development, the human recombinant urotensin II (UII) was modified by labeling europium at its N-terminal position (Eu-UII) and used as a fluorescent tracer. The microsomal membrane fraction of UT receptor was prepared from HEK293 cells stably expressing the human UT receptor. The 50% inhibitory concentration (IC(50)) values of UII from competition binding assays with Eu-UII were 2.76 nM, which is very similar to that of fluorescence polarization (FP)-based UT receptor binding experiment (2.18 nM). Comparing with the FP-based receptor binding assay for UII (Z' factor, 0.36), the current TRF assay presented improved Z' factor (0.76) with a relatively higher signal-to-background ratio (1.5 and 2.1, respectively). The known high-affinity UT receptor antagonists, palosuran and SB657510, exhibited IC(50) values of 23.6 and 73.4 nM, respectively, which were consistent with the IC(50) values from FP-based receptor binding assay (30.6 and 78.7 nM, respectively). These results suggest that our filtration-based TRF UT receptor binding assay can achieve the desired sensitivity with higher reproducibility to adapt for the high-throughput screening of compound libraries.
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Sulfonamides
/
Urotensines
/
Évaluation préclinique de médicament
/
Europium
/
Tests de criblage à haut débit
/
Polarisation de fluorescence
Type d'étude:
Diagnostic_studies
/
Screening_studies
Limites:
Animals
/
Humans
Langue:
En
Journal:
Assay Drug Dev Technol
Sujet du journal:
FARMACOLOGIA
Année:
2011
Type de document:
Article
Pays de publication:
États-Unis d'Amérique